1997
DOI: 10.1016/s0009-9236(97)90151-x
|View full text |Cite
|
Sign up to set email alerts
|

Effect of renal impairment on the pharmacokinetics and pharmacodynamics of desirudin

Abstract: A dose reduction by a factor of six is recommended for persons with severe renal failure.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
43
0

Year Published

2002
2002
2017
2017

Publication Types

Select...
6
3
1

Relationship

0
10

Authors

Journals

citations
Cited by 50 publications
(43 citation statements)
references
References 18 publications
0
43
0
Order By: Relevance
“…Compared to argatroban, its use is not recommended in patients with renal failure, as it is cleared primarily by the kidneys, but it can be used in patients with impaired liver function [117]. Desirudin is used for VTE prophylaxis in patients undergoing total hip replacement [118].…”
Section: Desirudin (Iprivask)mentioning
confidence: 99%
“…Compared to argatroban, its use is not recommended in patients with renal failure, as it is cleared primarily by the kidneys, but it can be used in patients with impaired liver function [117]. Desirudin is used for VTE prophylaxis in patients undergoing total hip replacement [118].…”
Section: Desirudin (Iprivask)mentioning
confidence: 99%
“…59 Hirudin is cleared via the kidneys so its dose must be adjusted in patients with renal insufficiency. 60 Although hirudin has been evaluated in acute coronary syndromes [61][62][63][64][65][66][67][68][69][70] and for prevention and treatment of DVT, [71][72][73] its development for these indications is no longer being pursued. For acute coronary indications hirudin was marginally more effective than heparin but caused more bleeding (Table 5).…”
Section: Hirudinmentioning
confidence: 99%
“…The half-life of hirudin after subcutaneous injection is 120 minutes, whereas it is 60 minutes after intravenous injection. 43 Hirudin is cleared in the kidneys and thus dosing must be adjusted in patients with renal failure; this is feasible because the anticoagulant effect of hirudin may be monitored by aPTT levels. There is no specific antidote for hirudin.…”
Section: Selective Inhibitors Of Thrombin Formationmentioning
confidence: 99%